This study investigates a novel nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues to elicit robust antitumor T cell responses. Using KRAS G12D mutations as neoantigens, the researchers found that vaccination with SLP-Lpx (synthetic long peptides in cationic lipoplexes) stimulated both CD4⁺ and CD8⁺ T cells, suppressing tumor growth in a CD8⁺ T cell-dependent manner, more effectively than naked synthetic peptides. Combining SLP-Lpx vaccines with a checkpoint inhibitor led to significant tumor growth suppression, suggesting that targeted delivery of neoantigen-derived peptides to the spleen via lipoplexes enhances antitumor immunity.
Publisher
npj Vaccines
Published On
Nov 12, 2020
Authors
Carlos A. Arbeláez, Juan Estrada, Melissa A. Gessner, Charles Glau, Agnieszka B. Morales, Deanna Mohn, Hyewon Phee, J. Russell Lipford, James A. Johnston
Tags
nanoparticle vaccine
neoantigen peptides
antitumor T cell responses
KRAS G12D mutations
SLP-Lpx
tumor growth suppression
Related Publications
Explore these studies to deepen your understanding of the subject.